Case Study: Retrofitting Two New High-Purity Water Systems
GlaxoSmithKline (GSK)’s R&D Biopharmaceutical Pilot Plant in Upper Merion, PA is a R&D clinical trial material (CTM) manufacturing facility with an aggressive processing schedule that requires minimal shutdown interruptions. Utility reliability is paramount to achieve production demands and regulatory quality requirements. To meet the utility demands for increased CTM output, a capital investment project was required to replace the existing, obsolete high purity water (HPW) generation system and water-for-injection (WFI) generation system with new, reliable technology. This article describes how the new systems were designed and installed in a challenging space to ensure redundancy and improve sustainability.
Read this article from Pharmaceutical Technology’s 2017 Biologics and Sterile Drug Manufacturing eBook.
View other articles in the 2017 Biologics and Sterile Drug Manufacturing eBook.
|
|---|
|
Columnists
 |
Ingredients Insider Cynthia ChallenerEfficiency Demands Drive Advances in API Labs |
 |
Regulatory Watch Jill Wechsler FDA Clarifies Worldwide Inspection Policies |
 |
EU Regulatory Watch Sean Milmo Curbing Drug Shortages in Europe |
Webcasts
Outsourcing
Cambrex Development Center in North Carolina Focuses on Continuous Flow
Cambrex will create a new center of excellence for API process development and clinical supply at its High Point, NC facility and expand its API manufacturing facility in Italy.
Lonza Opens Monoplant for Clovis Oncology’s Rubraca
Clovis Oncology and Lonza celebrated the grand opening of a dedicated production train at Lonza’s Visp, Switzerland site for manufacturing Rubraca (rucaparib).
Outsourcing Development: Small-Scale to Commercial
Industry experts discuss the formulation and development issues that should be considered when addressing scale up from small-scale batches to commercial production.
Sponsored Links
